Last updated: May 26, 2026
Jublia is a topical antifungal drug product containing efinaconazole. Supplier sourcing for the finished product and for efinaconazole active pharmaceutical ingredient (API) is concentrated among a limited set of specialty chemical and dosage-form contract manufacturing organizations (CMOs) with capabilities in topical azole formulations and antifungal-grade raw material handling.
Which companies supply the efinaconazole API used in Jublia?
Short answer: Efinaconazole API supply is typically handled by specialty chemical manufacturers and API traders with regulatory-ready sourcing. The most reliable route to identify exact API suppliers for Jublia batches is through procurement records, DMF access (where held), and CGMP batch-manufacturing records tied to the NDA/ANDA supply chain rather than public marketing claims.
What is the supply structure for efinaconazole API?
Most efinaconazole drug product supply chains follow this pattern:
- API producers: make and purify efinaconazole under GMP and provide CoA and regulatory documentation.
- API distributors: resell API from one or more underlying plants, often standardizing lead times.
- Finishers/CMOs: formulate and fill topical products like nail solutions, usually requiring:
- antifungal raw material controls,
- viscosity and solvent system controls,
- container closure system qualification for nail lacquer type products.
API grade controls that affect supplier qualification
For antifungals like efinaconazole, supplier qualification commonly centers on:
- assay and impurity profile (azole-related impurities)
- residual solvent limits
- particle and filtration controls relevant to solution clarity
- stability under packaging conditions
Who manufactures the finished dose form for Jublia (efinaconazole topical solution)?
Short answer: Jublia’s finished product manufacturing is performed by branded-license supply chains where the applicant/holder manages one or more CMOs and/or internal manufacturing sites. Exact site-level CMO names are generally not fully visible in public product listings and are confirmed through facility registrations tied to the marketing NDA and, in litigation contexts, through discovery.
What manufacturing capabilities are required for Jublia-type topical nail solutions?
Key CMO capability requirements for Jublia-style nail solutions include:
- controlled solvent and excipient system for nail penetration
- spray- or brush-applicator packaging compatibility
- fill accuracy and dose uniformity
- microbial quality controls for solution products
- stability program for nail lacquer type packaging
How does Jublia’s supply chain differ from generics and authorized products?
Short answer: Generic entry does not eliminate the need for compliant API and CMO formulation. It shifts leverage toward competitive CMOs and alternative API sources, while creating additional qualification pressure around bioequivalence-relevant product quality and nail-film performance.
What sourcing changes when a generic is developed?
Generic and “drop-in” product development commonly changes sourcing inputs:
- one or more alternative API suppliers if compatible with the regulatory file
- formulation line changes to replicate viscosity, solvency, evaporation profile, and film formation
- packaging substitution risk that must be controlled through bridging studies
What do typical procurement routes look like for Jublia suppliers?
Short answer: Procurement for efinaconazole topical products is commonly executed through branded supply agreements for the finished product and through qualified vendor lists for APIs.
Routes used by buyers (manufacturers, distributors, packers)
- Direct branded procurement of finished Jublia
- API procurement via qualified vendor lists held by development companies
- CMO sourcing for manufacturing slots under quality agreements and technical transfer
What supplier data sources are used to verify “who supplies Jublia”?
Short answer: In practice, buyers validate suppliers using a combination of regulatory and commercial evidence.
Evidence sources (industry standard)
- FDA databases of drug establishments and facility registrations
- NDA/DMF linkages (where accessible to the developer or via granted right of reference)
- CoA and batch release documentation from manufacturers
- quality agreements and vendor qualification packages
- import/export records that identify manufacturing and re-labeling points
- patent litigation discovery that names facilities and sourcing
How do supply constraints affect Jublia availability and lead times?
Short answer: Availability risk is usually tied to:
- API batch yield or impurity excursions,
- CMO line capacity for topical antifungal solution fill,
- packaging component supply (closures, brushes, bottle housings),
- solvent or specialty excipient availability.
Key Takeaways
- Jublia is efinaconazole topical nail therapy; supplier sourcing splits between efinaconazole API providers and topical solution CMOs that formulate and package the finished product.
- Public sources rarely identify the exact named plant-level suppliers of API or finishers for specific lots. Buyers confirm through regulatory facility data, DMF/NDA linkages, and batch release documents.
- Generic development increases competition for CMOs and API sourcing but adds qualification requirements tied to solution quality, nail-film behavior, and packaging.
FAQs
-
How do I find the efinaconazole API manufacturer for Jublia batches?
Use regulatory facility traceability plus batch CoA and DMF/NDA linkage confirmation.
-
Are there multiple API sources for efinaconazole in the market?
Typically yes through specialty chemical producers and distributors, but qualification governs which sources are acceptable to a specific NDA/ANDA.
-
What packaging components are critical for Jublia-like topical nail solutions?
Bottle and closure compatibility, brush applicator performance, and leak/evaporation control drive stability and dose delivery.
-
Do generics require the same efinaconazole API supplier as the branded product?
Not necessarily, but they must meet the regulatory quality profile and impurity/spec standards in their regulatory file.
-
What supply bottlenecks most often affect topical antifungal availability?
API impurity excursions, solvent and excipient supply, and fill-pack line or packaging component shortages.
References
- FDA. Drugs@FDA. “Jublia (efinaconazole)”. U.S. Food and Drug Administration.
- FDA. Drug Establishments Current Registration Site. U.S. Food and Drug Administration.
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
